摘要
目的研究索拉非尼治疗非手术肝癌患者的临床疗效。方法将临床收治的41例肝癌患者随机分为两组,PIAF组21例采用PIAF(顺铂、阿霉素、氟尿嘧啶和人重组α-干扰素)化疗方案;PIAFS组20例肝癌患者采用PIAF联合索拉非尼化疗(PIAFS)方案。两组均化疗3个疗程,每个疗程结束时,统计两组治疗方案肝癌患者的1年生存率,B超复查癌灶大小,生化检测肝癌患者血清AFP-L3(甲胎蛋白异质体)、ALT(谷丙转氨酶)和AST(谷草转氨酶)的水平。结果 PIAFS组相比PIAF组化疗后肝癌患者的有效率和生存率明显提高,AFP-L3、ALT和AST与化疗前比较明显降低,且维持相对稳定。结论索拉非尼可降低肝癌患者AFP-L3、ALT和AST,稳定肝癌患者病情和提高患者生存率。
Objective To study the clinical efficacy of non operation sorafenib in treatment of patients with hepatocellular carcinoma.Methods 41 liver cancer patients were involved in the present study.21 cases were treated with PIAF（cisplatin,doxorubicin,fluorouracil and recombinant humanα-interferon）chemotherapy.Others were treated with sorafenib combined with PIAF（PIAFS）.Both of them were treated three courses.The two-year survival rate was observed.The tumor sizes were detected by B ultrasonic.The serum AFP-L3（alpha-fetoprotein）,ALT（alanine aminotriansferase）and AST（glutamic oxalacetic transaminase）detected by biochemical instruments.Results Compared with PIAF,the survival rate of HCC patients after PIAFS therapy was significantly improved.The AFP-L3,ALT and AST decreased significantly compared with the previous chemotherapy.Conclusion The AFP-L3,ALT and AST of HCC patients were reduced after sorafenib chemotherapy.HCC patient＇s condition did not continue to deteriorate,and the survival rate of HCC patients was increased.
出处
《西部医学》
2015年第7期1016-1018,1021,共4页
Medical Journal of West China
基金
四川省卫生厅科研课题(120392)
